[Prevalence of psychoactive drug consumption in an obese population].
OBJECTIVE
To establish the prevalence of psychoactive drug consumption in an obese population.


METHODS
We collected data from the clinical records of obese patients attending the Endocrinology and Nutrition Department and Psychiatry Department of Hospital del Mar between June 2005 and May 2006 (n=259). We recorded anthropometric, epidemiological and toxicological data. We also investigated the prevalence of concomitant diseases in this population.


RESULTS
Psychoactive drugs were consumed by 37% of obese patients, mainly antidepressants (27%), anxiolytics, sedatives and hypnotics, and anticonvulsants. Moreover, 15% of all patients received combination treatment with two or more psychoactive drugs, mostly the association of an antidepressant and an antiepileptic drug.


CONCLUSIONS
The prevalence of psychoactive drug consumption in our sample was higher than prevalence data observed in the general population, with antidepressant consumption being three-fold higher.
Cerdá Esteve
Maria A
MA
Servicio de Endocrinología y Nutrición, Hospital Universitari Arnau de Vilanova de Lleida, Universitat de Lleida, Lleida, España. dbtafalla@gmail.com
Barral Tafalla
Diego
D
Gudelis
Mindaugas
M
Goday
Albert
A
Farre Albaladejo
Magi
M
Cano
Juan F
JF
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy / Q000453:epidemiology; D015897:Comorbidity; D003863:Depression / Q000188:drug therapy / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D004363:Drug Utilization / Q000706:statistics & numerical data; D004827:Epilepsy / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000453:epidemiology; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology* / Q000523:psychology; D010003:Osteoarthritis / Q000453:epidemiology; D019338:Polypharmacy; D015995:Prevalence; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D013030:Spain / Q000453:epidemiology
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D006993:Hypnotics and Sedatives; D011619:Psychotropic Drugs